{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009717","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.289264+00:00","generated_at":"2026-05-25T00:57:20.419676+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"TNF Pharmaceuticals holds investor call on Isomyosamine R&D progress","bullets":["Conference call conducted March 6, 2025 to discuss research and development of lead compound Isomyosamine.","Transcript furnished as Exhibit 10.1; no specific clinical or financial data provided in the available text.","Company noted it undertakes no obligation to update the materials."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009717","json":"https://secwatch.observer/filing/0001493152-25-009717.json","markdown":"https://secwatch.observer/filing/0001493152-25-009717.md","text":"https://secwatch.observer/filing/0001493152-25-009717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315225009717/0001493152-25-009717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315225009717/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:57:20.419676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}